Cargando…

Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

SIMPLE SUMMARY: Glioblastoma is a type of brain cancer that remains incurable. Despite multiple past and ongoing preclinical studies and clinical trials, involving adjuvants to the conventional therapy and based on molecular targeting, no relevant benefit for patients’ survival has been achieved so...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vilar, Juliana B., Christmann, Markus, Tomicic, Maja T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139489/ https://www.ncbi.nlm.nih.gov/pubmed/35626024 http://dx.doi.org/10.3390/cancers14102416

Ejemplares similares

Targeting anticancer drug-induced senescence in glioblastoma therapy
por: Tomicic, Maja T., et al.
Publicado: (2018)

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment
por: Schwarzenbach, Christian, et al.
Publicado: (2021)

Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination
por: Reich, Thomas R., et al.
Publicado: (2021)

Business Notes: Where to Go for Holiday Goods
Publicado: (1871)

The peritumoral brain zone in glioblastoma: where we are and where we are going
por: Giambra, Martina, et al.
Publicado: (2022)

Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma
por: Lewitzki, Victor, et al.
Publicado: (2019)

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
por: Tomicic, Maja T., et al.
Publicado: (2015)

13 Ebola virus: where does it come from and where is it going?
por: Murphy, Frederick A., et al.
Publicado: (1998)

c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF
por: Christmann, Markus, et al.
Publicado: (2006)

Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage
por: Christmann, Markus, et al.
Publicado: (2010)

Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14(ARF)-Mediated Sustained p53 Activation
por: Tomicic, Maja T., et al.
Publicado: (2021)

Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence
por: Allmann, Sebastian, et al.
Publicado: (2020)

Moving Beyond Heading. How Does the Brain Reconcile where we are Going with where we Want to Go?
por: Wann, John
Publicado: (2011)

Radiochemotherapy
Publicado: (1998)

Where does it come from, where does it go? The role of the xylem for plant CO(2) efflux
por: Gessler, Arthur
Publicado: (2017)

Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity
por: Tomicic, Maja T., et al.
Publicado: (2010)

Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation
por: Niewald, Marcus, et al.
Publicado: (2011)

Where does public funding for HIV prevention go to? The case of condoms versus microbicides and vaccines
por: Peters, Anny JTP, et al.
Publicado: (2010)

Oral GLP1 Analog: Where Does the Tide Go?
por: Gardner, Hannah, et al.
Publicado: (2020)

Molecular targeted agents—where we are and where we are going
por: Yan, Li
Publicado: (2013)

Where is APC going?
por: Mimori-Kiyosue, Yuko, et al.
Publicado: (2001)

Where are we going?
por: Pawl, Ronald P.
Publicado: (2010)

Where is science going?
por: Planck, Max Karl Ernst Ludwig, et al.
Publicado: (1933)

Where is crystallography going?
por: Grimes, Jonathan M., et al.
Publicado: (2018)

Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy
por: Schnöller, Leon Emanuel, et al.
Publicado: (2022)

FKBP Ligands—Where We Are and Where to Go?
por: Kolos, Jürgen M., et al.
Publicado: (2018)

Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?
por: Barra, Fabio, et al.
Publicado: (2019)

Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy
por: Grah, Josip Joachim, et al.
Publicado: (2013)

Predicting Molecular Models: Where Are We Going?
por: Ratta, Raffaele, et al.
Publicado: (2015)

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
por: Reich, Thomas R., et al.
Publicado: (2017)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Where We Are and Where We Are Going in Nut Research
por: Salas-Salvadó, Jordi, et al.
Publicado: (2023)

COVID-19: Where We Are and Where We Are Going
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9lqmtcn5jdrp5037c8cku8ront